Home LiteratureArticle Details
PMID: 7499965 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma.

Journal of leukocyte biology ·Vol. 58 ·No. 6 ·1995-12-00 ·Pages 675-82

Aida Y, Kusumoto K, Nakatomi K, Takada H, Pabst MJ, Maeda K

Abstract

When incubated with lipopolysaccharide (LPS) in the presence of plasma, neutrophils become primed for enhanced release of superoxide in response to triggering by formyl-Met-Leu-Phe (fMLP). The effect of LPS on phagocytes is inhibited by a synthetic lipid A precursor, LA-14-PP (lipid IVa) or by LPS from Rhodobacter sphaeroides (Rs). We studied the mechanisms by which LA-14-PP or Rs-LPS inhibited LPS-induced responses. When neutrophils were exposed to LA-14-PP or Rs-LPS for 3 min and then to Escherichia coli-LPS, the antagonists inhibited priming for superoxide release, and also blocked up-regulation of CD11b and adherence. This inhibition was dependent on plasma, was not overcome by higher amounts of E. coli-LPS or plasma, and was not observed at 0 degrees C, suggesting that E. coli-LPS was not able to interact with its receptor or other cellular recognition molecule in neutrophils that had been exposed to the antagonists. The alternative possibility that LA-14-PP or Rs-LPS depleted a plasma cofactor, resulting in inhibition of priming, was investigated by using LPS from Porphyromonas gingivalis (Pg) and Bordetella pertussis (Bp). These LPS primed neutrophils in a plasma-dependent and CD14-dependent manner, but were not blocked by LA-14-PP or Rs-LPS. When sub-optimal concentrations of plasma were exposed to LA-14-PP or Rs-LPS, and then mixed with Pg-LPS or Bp-LPS, followed by incubation with neutrophils, priming and up-regulation of CD11b were inhibited, and this inhibition was overcome by increasing the concentration of plasma. Binding of LPS-binding protein (LBP) in plasma to immobilized E. coli-LPS was inhibited by pre-incubation of plasma with LA-14-PP or Rs-LPS. Together with the result that treatment of plasma with anti-LBP antibody abolished the cofactor activity of plasma, these results indicated that LA-14-PP and Rs-LPS depleted LBP from plasma, resulting in inability of LPS to act on neutrophils. Thus LA-14-PP and Rs-LPS inhibited the action of LPS on neutrophils by at least two mechanisms, blocking of LPS receptor recognition and depletion of the cofactor LBP.

MeSH Terms
Acute-Phase Proteins Carrier Proteins/metabolism Glycolipids/pharmacology Humans Lipid A/analogs & derivatives,pharmacology Lipopolysaccharide Receptors/metabolism Lipopolysaccharides/antagonists & inhibitors,metabolism,pharmacology Macrophage-1 Antigen/analysis Membrane Glycoproteins N-Formylmethionine Leucyl-Phenylalanine/pharmacology Neutrophils/drug effects Plasma/metabolism Rhodobacter sphaeroides/chemistry Superoxides/metabolism Temperature
Chemicals
Acute-Phase Proteins Carrier Proteins Glycolipids Lipid A Lipopolysaccharide Receptors Lipopolysaccharides Macrophage-1 Antigen Membrane Glycoproteins lipid A precursors, bacterial lipopolysaccharide-binding protein Superoxides N-Formylmethionine Leucyl-Phenylalanine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Aida Y
Department of Periodontology and Endodontology, Faculty of Dentistry, Kyushu University, Fukuoka, Japan.
Kusumoto K
Nakatomi K
Takada H
Pabst M J
Maeda K
Article Info
Journal
Journal of leukocyte biology
Abbr.
J Leukoc Biol
ISSN
0741-5400
Published
1995-12-00
Pages
675-82
Language
English
Region
United States
NLM ID
8405628
Subset
IM
Grants
NIDCR NIH HHS · DE05494 · United States
NIDCR NIH HHS · DE11125 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com